Mike Clayman, MD

Chairman, Anokion
CEO, Flexion Therapeutics

Dr. Clayman is a co-founder of Flexion Therapeutics and served as its President, Chief Executive Officer, and as a director from its inception in 2007 to its acquisition by Pacira Biosciences in 2021. Read More

Patricia L. Allen

Patricia L. Allen brings over 20 years of financial and operations leadership experience at both publicly traded and private biotechnology companies.

Read More

Laura Brass, PhD, MBA

Managing Director, Novartis Venture Fund

Dr. Laura Brass is a Managing Director at NVF in Cambridge, MA, USA. Prior to joining NVF, Laura was a Managing Director at MPM Capital, and prior to that, she was a member of the founding management team and SVP of Business Development for TriNetX, a healthcare IT company focusing on big data analytics of live patient data for clinical research. Read More

Thomas Dyrberg, MD

Senior Advisor, Novo Ventures, Novo Holdings

Thomas joined Novo A/S in 2000. He is a member of the Boards of Directors of Allievex Inc. and Anokion SA. Read More

Deborah Geraghty, PhD

Chief Executive Officer and President, Anokion

Dr. Geraghty joined Anokion in 2018 as Chief Business Officer and was most recently Chief Operating Officer of the company. Dr. Geraghty brings more than 20 years of extensive experience in the life sciences industry across corporate and portfolio strategy, commercial, and finance. Read More

Jeffrey Hubbell, PhD

Co-founder, Chief Scientific Advisor

Jeff is a professor and founder of the Institute of Bioengineering at the Ecole Polytechnique Fédérale de Lausanne (Swiss Federal Institute of Technology, EPFL), and a professor at the Institute of Molecular Engineering at the University of Chicago. Read More

Dhavalkumar Patel, MD, PhD

Chief Scientific Officer, UCB SA

Dhaval is a physician scientist who serves as an Executive Vice President and Chief Scientific Officer at UCB in Brussels, Belgium, and on the Boards of Directors for several biotech companies. Read More

Harry Welten

Former Chief Financial Officer, Cytos AG

Harry Welten, MBA, spent more than twenty years in international senior executive functions, sixtee of which as chief financial officer in biotechnology companies (privately as well as publicly held). Read More

Tom Woiwode, PhD

Managing Director, Versant Ventures

Tom has been with Versant Ventures since 2002, serving as a Venture Partner since 2008 and a Managing Director since 2014. Read More